Business Context and Reporting Period
This Form 8-K is a current report filed by Eyenovia, Inc. (not Hyperion Defi, Inc.) on December 29, 2020. The registrant is a Delaware corporation with its principal executive offices in New York, New York, and its common stock trades on the Nasdaq Capital Market under the symbol "EYEN". The company is classified as an emerging growth company.
Key Financial Metrics
This filing is a current report regarding a specific corporate event and does not contain financial statements. Consequently, there are no reported values for revenue, profit, cash flow, margins, debt, or liquidity in this document.
Material Changes
The material event reported is the submission of a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for MydCombi, a unique fixed combination mydriatic (pupil dilation) agent. This submission occurred on December 29, 2020.
Guidance, Outlook, and Risks
Management commentary is limited to the announcement of the NDA submission. The filing does not provide specific financial guidance, future outlook projections, or a detailed discussion of risks and contingencies beyond the standard regulatory context of an NDA submission. No unusual items or financial contingencies are disclosed in this text.
Investor Verification Checklist
- Verify the status of the FDA review for the MydCombi New Drug Application.
- Confirm the company name is Eyenovia, Inc., as the input metadata referenced "Hyperion Defi, Inc." which is incorrect for this filing.
- Review the attached press release (Exhibit 99.1) for detailed clinical data or regulatory timelines not included in the 8-K summary.
- Check subsequent filings for the FDA's decision on the NDA.